# Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

> **NCT01833520** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Ra-223 Dichloride

## Key facts

- **NCT ID:** NCT01833520
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-16
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-04-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833520, "Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01833520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*